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Abstract
Background: Lung cancer often exhibits molecular changes, such as the overexpression of the ErbB1 gene. ErbB1
encodes epidermal growth factor receptor (EGFR), a tyrosine kinase receptor, involved mainly in cell proliferation
and survival. EGFR overexpression has been associated with more aggressive disease, poor prognosis, low survival
rate and low response to therapy. ErbB1 amplification and mutation are associated with tumor development and
are implicated in ineffective treatment. The aim of the present study was to investigate whether the ErbB1 copy
number affects EGFR expression, cell proliferation or cell migration by comparing two different cell lines.
Methods: The copies of ErbB1 gene was evaluated by FISH. Immunofluorescence and Western blotting were
performed to determine location and expression of proteins mentioned in the present study. Proliferation was
studied by flow cytometry and cell migration by wound healing assay and time lapse.
Results: We investigated the activation and function of EGFR in the A549 and HK2 lung cancer cell lines, which
contain 3 and 6 copies of ErbB1, respectively. The expression of EGFR was lower in the HK2 cell line. EGFR was
activated after stimulation with EGF in both cell lines, but this activation did not promote differences in cellular
proliferation when compared to control cells. Inhibiting EGFR with AG1478 did not modify cellular proliferation,
confirming previous data. However, we observed morphological alterations, changes in microfilament organization
and increased cell migration upon EGF stimulation. However, these effects did not seem to be consequence of an
epithelial-mesenchymal transition.
Conclusion: EGFR expression did not appear to be associated to the ErbB1 gene copy number, and neither of
these aspects appeared to affect cell proliferation. However, EGFR activation by EGF resulted in cell migration
stimulation in both cell lines.
Keywords: Epidermal growth factor receptor, Lung cancer, Epidermal growth factor, Proliferation, Tyrosine kinase
inhibitor, Cell migration
Introduction
Lung cancer is the most common type of cancer in men
and women worldwide, and it is the main cause of cancer-
related death in the United States, Europe, Japan and
China [1-5]. Lung cancer is usually classified as small cell
lung cancer (10-15% of cases, associated with smoking),
non-small cell lung cancer [(85-90% of cases) also
classified as squamous cell carcinoma, adenocarcinoma or
large cell carcinoma], or carcinoid tumors of the lung (less
than 5% of cases) [6].
Lung cancer cells frequently manifest alterations in their
molecular genetics, including changes in epidermal
growth factor receptor (EGFR) expression. EGFR is a re-
ceptor encoded by the ErbB1 gene, which is located in the
7p12 region of chromosome 7. EGFR is a 170 kDa trans-
membrane glycoprotein, which contains an extracellular
domain, a transmembrane region and a tyrosine kinase
domain in the cytosol [7,8]. EGFR is activated by its
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ligands (EGF, TGF-α, amphiregulin, betacellulin, heparin
or epiregulin) that bind to the extracellular domain, caus-
ing a conformational change and promoting homo- or
hetero-dimerization. This results in the autophosphoryl-
ation of the tyrosine kinase domain, thereby initiating an
intracellular signaling cascade [9]. After activation, EGFR
is internalized and promptly degraded by lysosomes or
recycled to the membrane [10].
EGFR phosphorylation can activate two major cytoplas-
mic signaling routes: RAS and PI-3 kinase/Akt. RAS acti-
vation is responsible for inducing a phosphorylation
cascade, leading to the activation of MAPKs, ERK1 and
ERK2, which regulate the transcription of molecules re-
lated to cell proliferation [11,12]. The signaling cascade
mediated by PI-3 kinase/Akt is responsible for maintaining
cell survival [13]. However, there are additional signals af-
fected by EGFR phosphorylation, for example, the activa-
tion of the transcription factor STAT. In addition to
proliferation and survival, EGFR can promote other phe-
nomena, such as migration, invasion, differentiation, inhib-
ition of apoptosis and angiogenesis [14]. The activation of
EGFR by EGF can also induce epithelial-mesenchymal
transition (EMT), which usually corresponds to increased
cell motility [15].
EGFR has been associated with disease aggressiveness,
poor prognosis, low survival rate, low response to therapy
and resistance to cytotoxic agents in some types of tumors
[16]. Considering these factors, the development of drugs
that target this protein, i.e., EGFR inhibitors, for use in the
treatment of lung cancer is gaining importance. ErbB1
gene mutations and amplification usually occur together,
and lung cancer cell lines that manifest both events exhibit
high levels of EGFR [17,18]. Amplification, mutation and
overexpression have been used as biomarkers to select pa-
tients for treatment with EGFR inhibitors.
The first inhibitors clinically available for the treatment
of non-small cell lung cancer, such as erlotinib and
gefitinib, block the tyrosine kinase domain by competing
with the ATP-binding site [19]. Humanized monoclonal
antibodies that compete with the EGFR-binding sites are
being evaluated, for example, cetuximab [19]. Certain mu-
tations in exons of the ErbB1 gene can interfere with the
effects of these EGFR inhibitors [20]. The response to
EGFR inhibitors depends on the type of EGFR mutation,
and many studies have shown the relationship between
mutations and EGFR inhibitors [21-24].
The relationship between changes in the ErbB1 gene
copy number and EGFR overexpression remains contro-
versial. The impact of each of these changes on cell biol-
ogy and tumor progression also requires further study.
Studies focusing on EGFR and ErbB1 in lung cancer cells
are required for a better understanding of the functions of
EGFR in tumor biology and for the development of new
drugs and new treatment guidelines.
In this study, we aimed to elucidate the relationship
between ErbB1 gene copy number and EGFR expression
in two cell lines derived from non small cell lung cancer.
The number of ErbB1 gene copies was not directly cor-
related with the EGFR expression. The activation of
EGFR by EGF was detected by p-EGFR presence in both
cell lines and did not promote cell proliferation when
compared to unstimulated cells. However, morphological
alterations and increased cell migration were observed
and the relation of these alterations with EMT was
analyzed.
Methods
Cell culture
The human non-small cell lung cancer A549 cell line was
obtained from ATCC, and the HK2 cell line was
established in our laboratory [25]. Both cell lines were cul-
tured in a 37°C humidified incubator in an atmosphere of
5% CO2 and maintained in Dulbecco’s Modified Eagle’s
Minimum Essential Medium (DMEM, Sigma, CA, USA)
supplemented with 10% fetal calf serum (FCS), (Cultilab,
Sao Paulo, Brazil). The AG1478 was purchased from
Merck, and the concentration used was 5 μM. The EGF
was purchased from Sigma-Aldrich, and the concentra-
tions used were 100 ng/mL and 200 ng/mL. The experi-
mental protocols were approved by the Ethics Committee
of the Institute of Biomedical Science, University of Sao
Paulo, Brazil (Protocol CEP-ICB n. 389/10).
Fluorescent in situ hybridization
Slides containing A549 cells were washed for 5 minutes in
2×SSC solution and 1 minute in deionized water. Next, the
slides were dehydrated in 70%, 90% and 100% ethanol for 1
minute each, and the sections were air-dried. Ten microli-
ters of ZytoVision SPEC EGFR/CEN 7 Dual Color probe
was added, and the samples were covered with a coverslip.
The coverslips were sealed with glue. Next, the slides were
denatured at 75°C for 5 minutes on a hotplate and trans-
ferred to a humidified chamber and hybridized overnight at
37°C. The next day, the glue was removed and the cover-
slips submerged in 1× Wash Buffer A at 37°C for 1 minute.
The slides were washed twice in 1× Wash Buffer A for 5
minutes at 37°C. After this, the slides were washed in PBSA
for 1 minute and incubated with TOPRO-3 in a humidified
chamber for 20 minutes. The excess TOPRO-3 was re-
moved by washing the slides in PBSA. Antifade Solution
was added to the slides, and the slides were covered with
coverslip and sealed. The images were obtained using a
confocal laser-scanning microscope (LSM 510 – ZEISS).
Immunofluorescence
The cells were cultured on coverslips in 35 mm dishes
containing an initial inoculum of 3 × 104 cells. The prep-
arations were washed with phosphate-buffered saline
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(PBSA) and fixed with 3.7% formaldehyde for 30 mi-
nutes. The cells were washed with PBSA again and
permeabilized with 0.5% Triton X-100 for 10 minutes.
After this time, the cells were washed with PBSA, and the
primary antibodies were added. The incubations with
antibodies were performed in a humidified chamber
overnight. The antibodies used were as follows: EGFR
(Santa Cruz 1:20), p-EGFR (Abcam 1:100) and anti-golgin
(Molecular Probes 1:50). The cells were washed with
PBSA again, and the secondary antibody (FITC or TRITC)
was added and incubated for 3 hours. The nuclei were
stained with propidium iodide, and actin was highlighted
with phalloidin-FITC. The coverslips were mounted on
slides using Vectashield Antifade (Vector, Burlingame,
CA, USA). The images were obtained using a confocal
laser-scanning microscope (LSM 510 – ZEISS).
Immunoblots
The medium was removed after the treatments, and the
cells were washed with PBSA and lysed with RIPA buffer
[50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 0.1% NP-40,
0.5% sodium deoxycholate, 1 mM EDTA and 2 mM
EGTA] containing 1 mM sodium orthovanadate, 1 mM
phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin and
10 mg/ml aprotinin. The lysates were centrifuged at
20000 × g for 5 minutes. The supernatants were collected,
and a BCA assay (Pierce Biotechnology, Rockford, USA)
was used to quantify the total protein concentration.
Thirty micrograms (30 μg) of protein from the total cell
lysates was fractionated by SDS-PAGE on a 10% gel, and
the separated proteins were transferred to a PVDF mem-
brane (Amersham Bioscience) (100 V, 250 mA, for 2
hours). A blocking solution (TBS, 5% milk and 0.05%
Tween 20%) was added to the membrane for 1 hour. The
membranes incubated with antibodies for the detection of
phosphorylated proteins were subjected to blocking with
5% BSA (containing the phosphatase inhibitors NaF and
orthovanadate). After blocking, the membranes were incu-
bated overnight with an anti-EGFR polyclonal antibody
(Santa Cruz) diluted at 1:300 and anti-p-EGFR (1:1000)
antibody. A β-Tubulin or β-actin antibodies (1:1000) was
used as a control to confirm the loading conditions of the
proteins in the gel. The membranes were washed with
TTBS (2 × 10 minutes) and TBS (2 × 10 minutes). The
immune complexes were detected using peroxidase-
conjugated antibodies to mouse or rabbit immunoglobulin
(added for 1 hour at room temperature) followed by ex-
posure using the ECL Western blotting detection kit
(Amersham Pharmacia). The ImageJ program was used
for the densitometric analyses.
Treatments and number of cells
The cells were cultured in 35 mm dishes with an initial
inoculum of 2 × 104 in medium supplemented with 2.5%
FCS. After 24 hours, the medium was changed, and differ-
ent concentrations of FCS, EGF (100 ng/ml; 200 ng/ml) or
AG1478 (5 μM) were added. The experimental groups were
as follows: control cells (10% FCS), starved control cells cul-
tured with 2.5% FSC (C2.5%FCS), cells stimulated with
EGF in 2.5% FCS medium (2.5%FCS + EGF), cells treated
with AG1478 in the 2.5% FCS medium (2.5%FCS +
AG1478), cells treated with AG1478 and stimulated with
EGF after 1 hour (2.5%FCS +AG1478 + EGF) and cells cul-
tured in 10% FCS medium containing EGF (10%FCS +
EGF). The cells were maintained in these conditions for 24,
48 and 72 hours. After this period, the cells were washed
three times with 500 mL PBSA. After removing the PBSA,
we added 500 mL trypsin and inactivated this enzyme with
500 mL of medium. The cells were quantified by counting
in flow cytometer (Guava EasyCyte Mini).
Cell cycle
The A549 and HK2 cells (3×104 cells/35×11 mm dishes)
were incubated for 24, 48 and 72 hours with the treatments.
The cells were harvested and fixed with 75% ice-cold metha-
nol at 4°C for 1 h. Cells were then washed with PBSA and
suspended in propidium iodide staining solution containing
200 μL of PBSA, 20 μL of ribonuclease (10 mg/mL) and
20 μL of propidium iodide (10 μg/mL). The cell suspensions
were incubated for 1 h at 4°C, and 5000 cells were analyzed
by flow cytometry in each group (EasyCyte Mini - Guava
Technologies).
Mitotic index
After the treatments, the cells were fixed with the same re-
agents described in the immunofluorescence section. The
nuclei were stained with propidium iodide for 15 minutes,
and the coverslips were mounted on slides with Vectashield
Antifade. The frequency of metaphases was determined in
the preparations using a confocal laser-scanning micro-
scope; 2000 cells per slide were counted.
Real time RT-PCR
The RNA extraction was performed using ChargeSwitch
Total RNA Cell Kits. The RNA was quantified using a
NanoDrop ND1000 Spectrophotometer. The expression
levels were determined by real time RT-PCR analysis
(Corbett Research - Rotor Gene 6000 real-time cycler)
using an AgPath-ID One-Step RT-PCR kit (Ambion) and
SYBR Green (Invitrogen). The qRT-PCR conditions were
as follows: 45°C for 10 minutes, 95°C for 15 minutes and 40
cycles [95°C for 15 seconds; Tm°C for 20 seconds; 72°C for
30 seconds] following the melt. The primers used were the
following: qEGFR_Right TCCTTTGGGGCATAGATCAG
and qEGFR_Left GCTGACCTGGAGGGAACATA (Tm
52°C), qVim_Right TCCAGCAGCTTCCTGTAGGT and
qVim_Left GAGAACTTTGCCGTTGAAGC (Tm 55°C),
qCyto18_Right GAGCTGCTCCATCTGTAGGG and
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qCyto18_Left CACAGTCTGCTGAGGTTGGA (Tm
55°C), qEcad_Right AAAGTGATGACCTCCCATGC and
qEcad_Left TACCTGCTCACGTCAAATGC (Tm 55°C).
The normalization was done against total RNA [26,27].
Wound healing assay
For the wound healing assay, the A549 and HK2 cells
(1×105 cells/35×11 mm dishes) were seeded and incubated
for 24 hours at 37°C and then treated according our treat-
ment schedules (C2.5%FCS, 2.5%FCS + EGF, 2.5%FCS +
AG1478). After achieving confluence, the cellular layer in
each plate was scratched using a plastic pipette tip. The
migration of the cells at the edge of the scratch was ana-
lyzed at 0, 24 and 48 hours, when microscopic images of
the cells were captured. The images were analyzed by
qCMA software [28].
Time-lapse microscopy
For time-lapse experiments A549 and HK2 cells were
culture (5×104 cells) in glass bottom dishes with 4 com-
partments. After 24 h cells in each compartment were
culture in one of following conditions: culture medium
with 2.5% FCS plus 100 ng/mL of EGF, culture medium
with 2.5% FCS plus 5 μM of AG1478, culture medium
with 2.5% FCS and culture medium with 10% of FCS.
Cells were observed for 12 h in a Biostation microscope
(Nikon), which maintained the temperature at 37°C and
atmosphere with 5% of CO2. Images were taken every 15
minutes using a 20× objective, and route and velocity of
30 cells of each group were determined by MTrackJ
plugin of ImageJ software.
Statistical analysis
The statistical analyses were performed using Minitab 15
software. The tests to determine the difference between
the control groups and treatments were as follows: one-
way ANOVA, two-way ANOVA (multiple comparisons
by Tukey) and Student’s t-test. The differences were con-
sidered significant at p ≤ 0.05.
Results
Lung cancer cell lines differ in the number of ErbB1 gene
copies and levels of EGFR expression
The number of ErbB1 gene copies was analyzed in one
hundred A549 and HK2 cell nuclei using the FISH method
with a dual staining probe for this gene and centromere 7.
The centromere 7 labeling, localized near the ErbB1 gene
on chromosome 7, was also quantified. The majority of
A549 cells presented 3 ErbB1 copies and 3 centromere 7
labels (Figure 1A). The number of ErbB1 copies ranged
from 4 to 9 copies, peaking at 5 to 6 copies per nucleus, in
the HK2 cells (Figure 1B). The amount of labeled centro-
mere 7 also varied in the HK2 cells (Figure 1B); some cells
presented more copies of centromere 7 than of the ErbB1
genes and some contained more copies of ErbB1 than
centromere 7, indicating a heterogenic cell population,
which suggests possible chromosome instability. The cellu-
lar location of EGFR was also investigated in both cell
types by immunofluorescence (Figure 2A). In the A549
cells, EGFR was detected at the cell borders, suggesting its
localization on the cell membrane, diffusely in the cyto-
plasm and in perinuclear clusters. However, in HK2 cells,
EGFR labeling was rather detected at the cell borders.
The lower levels of EGFR labeling in the cytoplasm sug-
gest that the HK2 cell line presents a lower concentration
of EGFR. Therefore, we investigated whether there were
differences in the levels of protein expression. Western
blotting experiments demonstrated that the HK2 cells
manifested reduced receptor expression levels compared
to the A549 cells (Figure 2B and C). Quantitative RT-PCR
revealed that levels of ErbB1 messenger RNA were higher
in the A549 cells than the HK2 cells (Figure 2D).
Determination of the cellular localization and activation
status of EGFR after EGF stimulation
A549 cells exhibited significant changes in EGFR distri-
bution after EGF stimulation. The localization of EGFR
to the cell borders was altered, and the receptor was lo-
cated in numerous small agglomerates dispersed in cyto-
plasm with the appearance of vesicles, and in clusters
near the nucleus (Figure 3A). HK2 cells presented some
possible cytoplasmic vesicles, but compared to A549
cells, the considerably fewer of these structures were
detected (Figure 3A). After EGF stimulation, EGFR was
located at the cell borders only in HK2 cells (data
not shown).
The Golgi apparatus was detected by immunofluores-
cence using an antibody against golgin. The histogram
in Figure 3B presents the intensity of the green (EGFR)
and red (golgin) signals in the cytoplasm at the selected
locations and it indicates where signals are co-localized.
The EGFR labeling co-localizes with the golgin immu-
nolocalization in the vesicle-like structures in A549 cells,
while HK2 cells did not present this co-localization
(Figure 3B).
The phosphorylated form of EGFR (p-EGFR) was ana-
lyzed by immunofluorescence in control and EGF-
stimulated cells. The A549 control cells did not present
p-EGFR labeling, but in the EGF-stimulated cells, p-EGFR
could be identified at vesicle-like structures in the cyto-
plasm (Figure 4A). The pattern of p-EGFR labeling was
similar to that of EGFR after EGF stimulation (Figure 3A),
suggesting that some of the vesicle-like structures in EGF-
stimulated cells likely contain p-EGFR. The HK2 cells
presented a different pattern: the phosphorylated form of
EGFR was at the borders of control cells and inside
vesicle-like structures in EGF-stimulated cells (Figure 4A).
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Western blotting was performed to evaluate the total
levels of EGFR (intracellular and cell surface) and p-EGFR
(Figure 4B). A549 cells maintained the same levels of
EGFR 1 hour after stimulation (EGF 1h) compared to con-
trol group. After 3 hours of EGF stimulation (EGF 3h) the
level of EGFR decreased expression in A549 cells. The
presence of the p-EGFR was not detected in control A549
cells (C 1h and C 3h), but after one hour of stimulation
(EGF 1h), the p-EGFR was detected, and after three hours
of EGF exposure (EGF 3h), the p-EGFR level was observed
to be decreased.
HK2 cells showed different responses to the same
treatment of EGF stimulation. A severe reduction of
EGFR was verified even after one hour of EGF stimula-
tion. However, p-EGFR protein was ready detected in
control cells (C1h and C3h). Additionally, after one hour
of EGF stimulation, it was possible to observe increased
levels of the p-EGFR protein, which subsequently de-
creased after this timepoint.
All together the results indicate different pathways of
EGFR after EGF stimulation. In A549 cells the synthesis
of new molecules of EGFR would compensate the deg-
radation of receptors after internalization. This was not
observed in HK2.
EGFR activation by EGF did not induce cell proliferation
Once we demonstrated that EGFR is phosphorylated by
EGF exposure in A549 and HK2 cells, the next step was to
determine if the EGFR activation contribute to cell prolif-
eration. Both cell lines were submitted to serum starvation
(2.5% FCS) followed by EGF addition, and the cell num-
bers were determined after 24, 48 and 72 hours.
There was no significant difference in the number of
cells between the groups of A549 cells at the examined
times (Figure 5A). The data analyses using Minitab 15 soft-
ware indicated a tendency towards decreased cell number
in the stimulated group (2.5% FCS + EGF) after 48 and 72
hours. Similar results were observed in the HK2 cell line,
no differences in the cell number were detected. However,
after 72 hours, the 2.5% FCS + EGF condition was associ-
ated with the least number of cells compared to the control
group (Figure 5A).
The cell cycle was analyzed in all groups in both cell
lines by flow cytometry, and the results are presented in
Table 1. The A549 cells stimulated with EGF presented a
slight increase in the frequency of cells in the G2/M phase
compared to the control cells. The C2.5% FCS condition
corresponded to 23.79% of cells in the G2/M phase at 48
hours and 21.55% at 72 hours. The cells treated with EGF
Figure 1 Quantification of ErbB1 gene copy number in A549 and HK2 cell lines. (A) The presence of centromere 7 (red) and ErbB1 gene
(green) was visualized by fluorescence in situ hybridization. The nuclei were visualized by interference contrast (DIC). (B) The copy number of
ErbB1 and centromere 7 per nucleus. One hundred cells of each strain were analyzed.
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(2.5% FCS + EGF) presented 25.59% of cells in G2/M at 48
hours and 24.05% at 72 hours. A decrease in the G1 phase
cell population was also observed in the EGF-stimulated
A549 cells; 56.14% of the stimulated cells at 48 hours and
58.79% at 72 hours were in G1 compared to 59.52% and
64.51% of control cells at 48 and 72 hours, respectively.
However, in HK2 cells, the results indicated that the EGF-
stimulated cells exhibited a small decrease in the G2/M
phase cell population compared to the control cells. In the
2.5% FCS group, 26.78% of cells were in G2/M at 48 hours
and 26.50% at 72 hours. Of the EGF-stimulated cells,
23.47% were in G2/M at 48 hours and 23.06% at 72 hours.
A consistent increase in the frequency of G1 cells was also
observed in the EGF-stimulated groups, corresponding to
49.58% of cells in G1 at 48 hours and 51.03% at 72 hours
in the stimulated cells compared to 46.40% and 42.60% of
control cells at 48 and 72 hours, respectively. There were
no significant changes in S phase in the groups analyzed.
To confirm whether the absence of proliferation stimu-
lus in response to the EGF was attributable to serum
deprivation, another experiment was designed. Instead of
serum starvation conditions, the cells were cultured in the
presence of 10% FCS containing 100 or 200 ng/mL EGF,
and the number of cells was quantified after 48 hours. The
addition of EGF to the 10% FCS medium did not increase
cell proliferation compared to the control cells cultured in
10% FCS medium alone (Figure 5B). These data are simi-
lar to the results presented in Figure 5A. The cell cycle
was also analyzed after 48 hours of EGF stimulation, and
the results (Table 2) were similar to those described above.
The frequencies of A549 cells in the G1 phase were
46.81% of the C10% cells, 41.28% of the 10%FCS +
100ngEGF cells and 42.10% of the 10%FCS + 200ngEGF
cells. Again, the EGF-stimulated cells exhibited a decrease
in the frequency of cells in G1. The frequencies of cells in
the G2/M phase were 21.92% of the control cells, 22.60%
of the 10%FCS + 100ngEGF cells and 23.55% of the 10%
FCS + 200ngEGF cells. In the HK2 cells, 38% of the con-
trol cells, 44.53% of the 10%FCS + 100ngEGF cells and
44.2% of the 10%FCS + 200ngEGF cells were in G1, indi-
cating an increase of cells in this phase after EGF treat-
ment. The proportions of HK2 cells in the G2/M phase
were 26.74% of the control cells, 26.52% of the 10%FCS +
100ngEGF cells and 28.39% of the 10%FCS + 200ngEGF
Figure 2 Cellular localization, expression and mRNA levels of EGFR. (A) Immunofluorescence was performed with an antibody against EGFR
(green). The nuclei were stained with propidium iodide (red). EGFR was identified at the cell membrane of both cell types and in clusters near
the nucleus in A549 cells. (B) EGFR expression in A549 and HK2 cells by Western blotting. (C) Quantification of EGFR expression. (D) RT-PCR
quantification of mRNA levels transcribed by the ErbB1 gene. All results are representative of three or more independent experiments.
*p≤ 0.05. Bars = standard deviation.
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cells. There were no significant changes in S phase in the
groups analyzed.
The mitotic indexes were determined by counting meta-
phases in the experimental groups. The frequency of
metaphases detected in the groups of A549 cells were
2.9% in C10%FCS, 1.20% in 10%FCS + EGF, 2.05% in
C2.5% and 1.35% in 2.5%FCS + EGF. In HK2 cells, the fre-
quencies were 1.15% in C10%FCS, 0.35% in 10%FCS +
EGF, 1.15% in C2.5% and 0.35% in 2.5%FCS + EGF. It was
observed that the EGF-stimulated groups (2.5%FCS +
EGF and 10%FCS + EGF) in all of the analyzed conditions
presented fewer metaphases compared to the control
groups (C10%FCS and C2.5%FCS) (Figure 5C).
Together, these data show that EGF stimulation is not
sufficient to promote cell proliferation through EGFR
signaling in the analyzed cell lines.
AG1478 did not interfere with cell proliferation
The effects of EGFR inhibition on cell proliferation were
also evaluated using a tyrosine kinase inhibitor (AG1478).
EGFR inhibition was confirmed by western blotting to de-
tect the p-EGFR protein. The p-EGFR protein was absent
after 1 hour of treatment, and it remained absent for 48
hours in both cell lines (Figure 6A). The analysis of cell via-
bility using the Via Count (GUAVA Technologies) reagent
in flow cytometry indicated that the inhibitor was not cyto-
toxic to the cells. The A549 control group contained 83.7%
viable cells, and the AG1478 inhibited group contained
88.9% viable cells. The HK2 control group contained 79.4%
viable cells, and the AG1478 inhibited group contained
83.7% viable cells.
Both cell lines were submitted serum starvation (2.5%
FCS) followed by EGF or AG1478 addition, and the
Figure 3 Detection of the EGFR cellular distribution after EGF stimulation. (A) Cells were cultured in medium containing 10% FCS and
treated with EGF (100 ng/ml) for one hour. EGFR (green) was detected in small and numerous vesicle-like agglomerates dispersed in the
cytoplasm and in clusters near the nuclei. The Golgi apparatus was detected using an antibody against golgin (red), and the nuclei were stained
with DAPI. (B) The histograms were generated using the profile display mode tool of LSM 510 version 3.2 software. The co-localization was
examined along a trace in a set of combined images. Some vesicle-like structures containing EGFR were co-localized with the Golgi apparatus
label. (see also Additional file 1: Figure S1).
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numbers of cells were measured after 48 hours. EGFR
inhibition did not have an effect on cell proliferation
compared to the controls (Figure 6B).
EGF elicited morphological changes that were suppressed
by AG1478
A549 and HK2 cells did not increase proliferation in
response to EGF exposure, but some cytoskeletal
morphological alterations were detected in the im-
munofluorescence preparations (Figure 7). The control
cells were organized into clusters, characteristic of epi-
thelial cells with cell-to-cell junctions (Figure 7A, A’,
B, B’). The EGF stimulation inhibited the organization of
HK2 and A549 cells into clusters, and the cells lost the
morphological characteristics of an epithelial cell line. The
EGF-stimulated cells with altered morphology appeared to
Figure 4 Location and expression of p-EGFR in A549 and HK2 cell lines. (A) Cells were cultured in medium containing 10% FCS (control) or
10% FCS and EGF (100 ng) for one hour. The labeling for p-EGFR is shown in green, and the nuclei were stained with propidium iodide (red).
(B) EGFR and p-EGFR proteins were detected by Western blotting, and β-tubulin protein was used as the loading control. The cells were
stimulated for one or three hours with EGF (EGF1 h/EGF3 h). The control cells were maintained in medium without EGF. EGFR expression in A549
and HK2 control cells could not be compared because of different time of film exposure.
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have lost cell polarity and exhibited stretching and spread-
ing. Other alterations detected were reduced adhesion
to the surrounding cells, altered organization of actin mi-
crofilaments and cytoplasmic protrusions (Figure 7C, C’, D,
D’). These cytoskeletal alterations were not observed in the
cells treated with AG1478 or with AG1478 plus EGF
(Figure 7E, E’, F, F’), indicating a potential recovery of
epithelial characteristics.
EGF promoted cell migration
We also investigated whether the morphological changes
elicited by EGF could contribute to cell migration using
a wound-healing assay and time lapse microscopy.
Wound-healing assay demonstrated that EGF stimulated
motility in the A549 and HK2 cells (Figure 8A and B).
After 48 h, A549 and HK2 control cells filled 73.45%
and 66.66% of the wound area, respectively and EGF-
stimulated A549 and HK2 cells filled 90% and 95% of
the wound, respectively. Cells treated with EGFR inhibi-
tor exhibited less motility than control cells, indicating
that the enhanced cell motility observed was due to
EGFR stimulation (Figure 8B). Also, the wound healing
was due to cell migration because EGF treatment did
not lead to increased cell proliferation.
Time-lapse microscopy experiments were performed
with cells cultured in a low density and with no directional
stimulus for cell migration. It was quantified the velocity
of 30 interphasic cells of each treatment group, consider-
ing the route of the cells during 12 h. EGF treatment stim-
ulated cell migration in both cell lines (Figure 8C). A549
and HK2 cultured in 10% FCS medium exhibited veloci-
ties of 10.5 μm/h and 5.7 μm/h, respectively; at 2.5% FCS
Figure 5 Determination of cell numbers after EGF stimulation. (A) A549 and HK2 cells were cultured in medium containing 10% FCS
(control), 2.5% FCS or 2.5% FCS plus EGF (100 ng), and the cells were counted after 24, 48 and 72 hours. Five thousand cells from each group
were analyzed in all experiments. (B) The cells were cultured in medium containing 10% FCS with or without EGF (100 or 200 ng)
supplementation. The cells were counted after 48 hours. In all experiments, 5000 cells from each group were analyzed. (C) The cells were fixed
after 48 hours of treatment (C10%FCS, 10%FCS + 100ngEGF, C2.5%FCS, 2.5%FCS + 100ngEGF), and the metaphases were quantified in a total of
2000 cells. All results are representative of three or more independent experiments. *p ≤ 0.05. Bars = standard deviation.
Table 1 Cell cycle analysis in A549 and HK2 cell lines after EGF (100ng) stimulation for 24, 48 and 72 hours
24h 48h 72h
Cell Cycle
phase
C10% FCS C2.5% FCS 2.5% FCS + EGF C10% FCS C2.5% FCS 2.5% FCS + EGF C10% FCS C2.5% FCS 2.5% FCS + EGF
G1 52.36% 58.63% 51.8% 57.01% 59.52% 56.14% 60.10% 64.51% 58.78%
A549 S 13.99% 14.87% 15.42% 12.56% 10.68% 9.72% 10% 9.44% 8.77%
G2/M 24.10% 19.60% 22.64% 24.99% 23.79% 25.59% 23.38% 21.55% 24.05%
G1 41.70% 45.70% 40.94% 43.66% 46.40% 49.58% 46.19% 42.60% 51.03%
HK2 S 24.45% 22.37% 25.82% 22.55% 21.86% 20.74% 21.94% 17.91% 17.26%
G2/M 39.75% 27.98% 28.78% 29.16% 26.78% 23.47% 27.54% 26.50% 23.06%
Lauand et al. Cancer Cell International 2013, 13:38 Page 9 of 15
http://www.cancerci.com/content/13/1/38
medium, 14 μm/h and 5.2 μm/h, respectively; after EGF
treatment A549 cells showed velocity of 23.3 μm/h and
HK2 cells exhibited velocity of 12 μm/h. A549 cells treated
with AG1478 showed lower velocity compared to 2.5%
FCS control group, but similar to the 10% FCS control
group. HK2 cells did not present significant changes in
velocity of AG1478 treated cells compared to control
groups.
It was observed a considerable standard deviation be-
tween velocities in both control and EGF-stimulated
cells in the same cell line. This indicates that cell behav-
ior can be heterogeneous among cells in the same cul-
ture. Despite the standard deviation, statistical analyses
demonstrate that EGF-stimulated cells presented higher
velocities compared to control cells.
Some of the proteins expressed by epithelial or mesen-
chymal cells were analyzed to investigate whether the
EGF-stimulated motility could be due to an epithelial-
to-mesenchymal transition (Figure 9A). In A549 cells,
no alterations in vimentin, cytokeratin 18 and E-
cadherin proteins were observed upon EGF stimulation.
HK2 cells exhibited a similar pattern of expression as
A549 cells but did not express E-cadherin. The E-
cadherin immunofluorescence images support the data
obtained by Western blotting (Figure 9B). Positive signal
for E-cadherin was observed in A549 cells immunofluor-
escence, and the protein was detected by western blot-
ting in this cell line. E-cadherin was not detected by
immunofluorescence or Western blotting in HK2 cells.
The mRNAs encoding these proteins were also evalu-
ated, and alterations related to epithelial-to-mesenchy-
mal transition were not detected (Figure 9C).
N-cadherin is another protein related to epithelial-to-
mesenchymal transition, expressed in mesenchymal
cells. HK2 cells did not present changes in mRNA levels
after EGF stimulation. A549 cells showed a discrete in-
crease in EGF stimulated cells compared to control
group cultured in 2.5% FCS (Figure 9C).
Discussion
We identified 3 ErbB1 gene copies in the A549 cell line, as
described previously [17], and heterogeneity in the ErbB1
gene copy number per nuclei in the HK2 cell line. It has
been reported that the MDA-MB-468 CD44+/CD24-/LOW
cell line contains different numbers of ErbB1 copies per
nucleus due to the asymmetric segregation of chromo-
somes during mitosis after the formation of breakage-
fusion-bridges [29]. The possibility of a fragile site near
the ErbB1 gene has also been suggested to contribute to
breaks near the ErbB1 gene region [30]. The HK2 cells are
comprised of 2.4% cells undergoing multipolar mitosis
and 3.7% micronucleated cells, suggesting that errors in
chromosome segregation may occur during mitosis in
these cells [31]. Thus, subpopulations of cells with differ-
ent ErbB1 gene copy numbers were observed in culture.
The HK2 cells presented higher genetic instability than
the A549 cell line.We also demonstrated that the HK2
cells presented more copies of the ErbB1 gene per nucleus
compared to the A549 cells. Previous studies have
reported an increased number of ErbB1 gene copies in
Table 2 Cell cycle analysis in A549 and HK2 cell lines
after 48 hours of EGF stimulation (100 or 200 ng/mL)
48 hours
Cell Cycle C10% 10%FCS 10%FCS
Phase FCS +100ngEGF +200ngEGF
G1 46.81% 4128% 42.10%
A549 S 14.7% 14.22% 14.21%
G2/M 21.92% 22.60% 23.55%
G1 38% 44.53% 44.2%
HK2 S 24.56% 23.69% 21.92%
G2/M 26.74% 26.52% 28.39%
Figure 6 EGFR inhibition by AG1478 did not interfere with cell
proliferation. (A) EGFR inhibition by AG1478 after 1 hour or
48 hours of treatment. (B) Determination of the cell numbers after
AG1478 inhibition. A549 and HK2 cells were cultured in medium
containing 10% FCS, 2.5% FCS, 2.5% FCS plus EGF (100 ng), 2.5% FCS
plus AG1478 and EGF or 2.5% FCS plus AG1478. The cells were
counted after 48 hours. Five thousand cells from each group were
analyzed in all experiments. All results are representative of three or
more independent experiments. *p≤ 0.05. Bars = standard deviation.
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tumors or cells derived from human lung carcinomas
[32,33]. Furthermore, the amount of EGFR was increased
in cells with ErbB1 amplifications and mutations [18]. It
was expected that the HK2 cells would express more
EGFR than the A549 cells, but the opposite was con-
firmed. The expression of EGFR was decreased due to a
reduction in the amount of mRNA transcribed by the
ErbB1 gene in the HK2 cells. It is possible that ErbB1 was
regulated by methylation, which commonly occurs in cer-
tain genes in lung cancer [34].
Many studies have focused on standardization to
utilize FISH for patient diagnosis and to determine
which patients to treat with EGFR inhibitors. Based on
these studies, samples of tumor cells with more than
three copies of ErbB1 and gene amplification would be
considered FISH positive and indicative of a poor prog-
nosis [35]. Thus, HK2 cells would be potentially FISH
positive despite their lower EGFR expression. The level
of EGFR expression did not seem to be related to the
ErbB1 gene copy number in either cell line.
Beyond the difference in gene copy number, we ob-
served alterations in the EGFR cellular localization and
expression level after EGF stimulation. The A549 and
HK2 cells contained EGFR in multiple vesicle-like struc-
tures in the cytoplasm after EGF treatment. This is in
agreement with other studies using A549 [15] and
another cell line derived from lung cancer, PC-14 [36].
Activated EGFR is endocytosed by clathrin-coated vesi-
cles, and the receptor can be recycled to the cell mem-
brane or retained in endosomes destined for degradation
in lysosomes. The receptor is recycled when the ligand de-
taches from it. The accelerated internalization removes
the activated receptor from membrane, directing it for
degradation [10]. The downregulation decreases EGFR
levels and cytoplasmic signaling in the cells [37,38]. The
vesicle-like structures containing EGFR observed in these
two cell lines could be associated with the EGFR degrad-
ation pathway, as EGF does not detach from EGFR in the
endosomes [10] and stimulates constant receptor internal-
ization [39]. Thus, the vesicle-like structures containing
the labeled p-EGFR would be destined for lysosomes.
The vesicles stained with the EGFR and golgin anti-
bodies, observed in A549 cells stimulated with EGF, are
most likely involved in the synthesis of this receptor.
Figure 7 Evaluation of the effects of EGF on cell morphology.
The control cells (A/A’: C10%FCS, B/B’: C2.5%FCS) were organized
into clusters with cell-cell junctions. The EGF (100 ng/ml)-stimulated
cells (C/C’: 10%FCS + EGF, D/D’: 2.5%FCS + EGF) manifested fewer
adhesions to the surrounding cells, alterations in the organization of
actin microfilaments and cytoplasmic protrusions. These alterations
induced by EGF were not identified in the cells treated with AG1478
(E/E’: 2.5%FCS + AG1478 + EGF, F/F’: 2.5%FCS + AG1478).
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This finding suggests that the receptors are destined
for the cell membrane to replace the degraded EGFR.
This EGFR production was not observed in HK2 cells.
Supporting these findings, western blotting indicated
persistent EGFR levels after EGF stimulation in A549
cells and a decrease in the EGFR levels after EGF stimu-
lation in HK2 cells.
Downregulation can contribute to an increase in the
response to therapy with EGFR inhibitors by regulating
the effects of EGFR signaling. For example, monoclonal
antibodies that bind the EGFR extracellular domain can
promote downregulation [40,41], and the endocytosis of
EGFR induced by EGF is closely related to the sensitivity
to the tyrosine kinase inhibitor gefitinib in non-small cell
lung cancer cell lines [42]. These reports suggest that
cancer cells that degrade EGFR may be more sensible to
treatments. Based on this suggestion, HK2 cells could be
considered less aggressive.
The EGFR phosphorylation promoted by EGF did not
affect the proliferation of A549 or HK2 cells. Several stud-
ies have correlated EGF with proliferation, but the results
are contradictory. Previous reports have demonstrated the
proliferation of A549 cells after EGF stimulation [43,44];
however, another report did not detect an induction of
proliferation by EGF in A549 cells [36]. We found that
EGF did not induce cell proliferation, and EGFR inhibition
by AG1478 also did not interfere with the number of cells.
Stimulation of A549 cells with EGF plus HGF, a c-Met
receptor ligand, had a synergistic effect on cell prolifera-
tion [45]. It is possible that the EGFR signaling pathway
alone was not sufficient to stimulate cell proliferation in a
monolayer culture.
Figure 8 EGF stimulates cell migration. (A) Wound healing assay was made in both cell lines with 24 and 48 hours of recovery. The groups
analyzed were: C2.5%FCS, 2.5%FCS + EGF (100ng/ml), 2.5%FCS + AG1478. Scale bars = 200 μm. (B) The graphics present frequency of wound
recovery in A549 and HK2 cells. We can observe that EGF-stimulated cells closed the wound faster than control and AG1478 inhibited cells.
All results are representative of three independent experiments. *p≤ 0.05. (C) Time-lapse microscopy experiments performed with no directional
stimulus for cell migration. It was quantified the velocity of 30 cells of each treatment group, considering the route of the cells during 12 h.
EGF treatment stimulated cell migration in both cell lines. Bars = standard deviation.
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It is possible that the AG1478 treatment did not affect
the number of cells because of the effects of other tyro-
sine kinase receptors that continued to signal and pro-
mote proliferation. An interaction among different types
of tyrosine kinase receptors has been described in gli-
oma; these receptors were co-activated and maintained
cytoplasmic signaling. By combining different inhibitors
against these receptors, it was possible to achieve a de-
crease in signaling [46]. The relationship between tyro-
sine kinase receptors is so close that some lung cancer
cell lines exhibited both EGFR and c-Met inhibition after
gefitinib treatment [47]. The activation of several tyro-
sine kinase receptors can potentiate cell signaling, and
the inhibition of multiple receptors can more efficiently
decrease the response.
Despite the absence of an effect on cell proliferation,
EGF-stimulated cells changed their morphology to EMT
like [48]. EMT induction by an EGF stimulus has already
been described in A549 cells [15,49]. However, alteration
in protein expression pattern (low cytokeratin, low
E-cadherin and high vimentin) associated with EMT
was not detected. Previous works have already demon-
strated that A549 and HK2 cells express vimentin
despite their epithelial origin [50]. EMT in these cells
can occur without an increase in vimentin expression
because the protein is already present. E-cadherin ex-
pression, other EMT marker was not detected in HK2
cells. A549 cells expressed E-cadherin , but the protein
levels did not decrease after EGF treatment as expected.
Another study has demonstrated that EMT was induced
by EGF in squamous cell carcinomas of the head and neck
without changes in E-cadherin expression [51]. Only A549
cells showed a discrete increase in the mRNA levels of
N-cadherin in EGF-stimulated cells. EMT cells, in the
mesenchymal stage, exhibit cell cycle arrest [48]. Al-
though, there was an increase in G1 cell population in the
EGF-stimulated HK2 groups, which can be suggestive of
cell cycle arrest. A549 and HK2 cells did not increase pro-
liferation rate after EGF stimulation. It may occur because
of cell cycle arrest, what would indicate EMT. Put all to-
gether, these data could not support the evidence of EMT.
Despite the absence of evidences of EMT, A549 and
HK2 cells showed increased cell motility and cell velocity
after EGF stimulation. Wound healing assay and time-
lapse analysis also demonstrated that A549 cells presented
higher motility compared to HK2 cells and that both cells
migrate with and without a migration stimulus. The
present results were not enough to confirm EMT by EGF
stimulus in A549 and HK2 cells, but they demonstrate that
EGF stimulated cell migration in A549 and HK2 cells.
Figure 9 Analysis of mRNA and protein related to EMT. (A) Vimentin, cytokeratin-18 and E-cadherin expression in A549 and HK2 cells by
Western blotting. The groups analyzed were: C10%FCS, C2.5%FCS, 2.5%FCS + EGF and 2.5%FCS + AG1478. Tubulin was used as loading control.
(B) Immunofluorescence was performed to C10%FCS, C2.5%FCS and C2.5%FCS + EGF groups using an antibody against E-cadherin (green) and
the nuclei were stained with propidium iodide (red). (C) RT-PCR quantification of mRNA levels of vimentin, cytokeratin-18, E-cadherin and
N-cadherin in A549 and HK2 cells. The groups were the same described in A. Bars = standard deviation.
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Conclusion
We have demonstrated that the number of ErbB1 gene
copies was not directly correlated with the EGFR expres-
sion, in A549 and HK2 cell lines. The activation or inhib-
ition of EGFR did not modify cell proliferation. However,
the stimulated cells exhibited morphological changes in
the cytoskeleton and increased cell motility.
Additional file
Additional file 1: Figure S1. Detection of the EGFR cellular distribution
after EGF stimulation of A549 cells. Cells were cultured in medium
containing 10% FCS and treated with EGF (100 ng/ml) for one hour.
EGFR (green) was detected in small and numerous vesicle-like
agglomerates dispersed in the cytoplasm and in clusters near the nuclei.
The Golgi apparatus was detected using an antibody against golgin (red),
and the nuclei were stained with DAPI. Mononucleated cells exhibiting
the Golgi apparatus localization similar to HK2 cells.
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